ESR1 and cancer: Downregulation of ER is hypothesized as a cause of acquired resistance to tamoxifen, although it is not downregulated in approximately a quarter of tumors with acquired resistance to tamoxifen and a fifth of the tamoxifen resistant cancers will go on to be responsive to treatment with an AI or a SERM (e.g., Fulvestrant) (81, 82).